Advertisement

Topics

Latest "FluGen" News Stories

14:28 EST 16th February 2019 | BioPortfolio

Here are the most relevant search results for "FluGen" found in our extensive news archives from over 250 global news sources.

More Information about FluGen on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about FluGen for you to read. Along with our medical data and news we also list FluGen Clinical Trials, which are updated daily. BioPortfolio also has a large database of FluGen Companies for you to search.

Showing "FluGen" News Articles, all 9

Relevant

NIH Using Vaccines from Madison Startup FluGen in New Clinical Trial

Researchers are testing a flu vaccine developed by FluGen, a Madison, WI-based startup, to determine whether it can protect recipients against strains of the virus that vary from the predominant strain flu predicted by health experts each year. Many people get a flu shot this time of year in hopes that it will help them […]


WI Watchlist: FluGen, Propeller Health, Gener8tor, EnSync

Here are some of the latest headlines from Wisconsin’s innovation community: —FluGen, a Madison-based company trying to develop a universal influenza vaccine, announced topline, preliminary data from a Phase 2 study that demonstrated its M2SR vaccine proved effective in countering a “mismatched” flu virus. The flu virus that makes its rounds each year doesn’t always [...

FluGen Completes Dosing of Phase 2 Study to Assess Effectiveness of Novel Influenza Vaccine Designed to Protect Against Mismatched Strains

—Influenza challenge virus genetically drifted by six years from vaccine strain— FluGen, Inc. announced today that all subjects have completed dosing in a first-of-its-kind clinical study which challenged subjects with an influenza virus that was intentionally mismatched by six years from the influenza strain utilized in FluGen’s M2SR vaccine. ...


FluGen Presents First-in-Human Phase 1a Safety and Immunogenicity Data with Novel M2SR Influenza Vaccine at ID Week

—Vaccine safe and well tolerated at all dose levels in trial— —Significant humoral, mucosal and T-cell responses produced by vaccine— —Goal of drifted/multi-season protection under evaluation in new, ongoing Phase 2 trial— FluGen, Inc. announced today that the company’s novel M2 deleted, single replication (M2SR) ...

WI Watchlist: Gener8tor, FluGen, Sift Healthcare, Titan Spine

Before everyone tucks into turkey later this week, let’s catch up on some recent headlines from Wisconsin’s high-tech sectors: —Wisconsin-based Gener8tor, which runs a network of programs that train and invest in startups, continues to expand. Its latest offering is the OnRamp Insurance Accelerator, an insurance technology-focused program that will be located in the Minneapolis [...

FluGen Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 13112018] Prices from USD $250

SummaryFluGen Inc FluGen is a developer of influenza vaccines and therapies. The company discovers, develops and commercializes new methods for the prevention and treatment of influenza infections. Its product include redeeflu, a nasal spray vaccine used to protect against influenza that contains mutations in the M2 gene of the virus. FluGen's redeeflu provides better efficacy against seasonal and...

FluGen Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 17042018] Prices from USD $250

SummaryFluGen Inc FluGen is a developer of influenza vaccines and therapies. The company discovers, develops and commercializes new methods for the prevention and treatment of influenza infections. Its product include redeeflu, a nasal spray vaccine used to protect against influenza that contains mutations in the M2 gene of the virus. FluGen's redeeflu provides better efficacy against seasonal and...

FluGen Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 11072018] Prices from USD $250

SummaryFluGen Inc FluGen is a developer of influenza vaccines and therapies. The company discovers, develops and commercializes new methods for the prevention and treatment of influenza infections. Its product include redeeflu, a nasal spray vaccine used to protect against influenza that contains mutations in the M2 gene of the virus. FluGen's redeeflu provides better efficacy against seasonal and...

FluGen’s M2SR Influenza Vaccine Succeeds in Phase 2 Human Challenge Trial Against a Highly Mismatched Virus

— Topline data shows first flu vaccine to demonstrate protection against a multi-season mismatched H3N2 strain in a human challenge clinical trial — — Intranasal administration of M2SR well-tolerated in trial — — Protection against influenza challenge correlated with serum response to M2SR — — Important step ...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks